Pharmaceutical Technology

MARCH 2, 2023

QN-023a is under clinical development by Hangzhou Qihan Biotechnology and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Gene Editing 100

Gene Editing Genetic Engineering Engineer Clinical Trials 100

Pharmaceutical Technology

MARCH 2, 2023

QN-019a is under clinical development by Hangzhou Qihan Biotechnology and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). GlobalData’s report assesses how QN-019a’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing Clinical Trials Clinical Trials Genetics 100

Pharmaceutical Technology

MARCH 22, 2023

Healthcare providers are under pressure to address the growing issue of substance use disorders. According to GlobalData’s Medical Device Pipeline Analytics, there are 61 products in development for treating substance abuse disorders classed as healthcare IT.

FDA Approval 130

FDA Approval Production Compliance Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 20, 2023

BI-685509 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.

Production 100

Production Manufacturing Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JULY 28, 2022

Cobitolimod, an agent being developed for patients with moderate to severely active UC, has both a novel MOA and a route of administration that is unique among marketed agents. Abivax is developing obefazimod, another agent with a first-in-class mechanism. GlobalData anticipates regulatory approval of Entyvio SC in the US next year.

Trials 246

Trials Marketing RNA Development 246

Pharmaceutical Technology

JUNE 5, 2023

BI-765063 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase I drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Production 100

Production Manufacturing Drugs Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. According to GlobalData, Phase III drugs for Glomerulonephritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Buy the report here.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

APRIL 3, 2023

Women’s health, and the development of technologies that cater to those specific needs, has long been a neglected and underfunded area. GlobalData is the parent company of Pharmaceutical Technology. Femtech gives women easier access to healthcare while also empowering them through greater control over their health, she added.

Regulation 130

Regulation Compliance Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here. Merck overview Merck, a subsidiary of E.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

JULY 21, 2022

As part of ESG (Environmental, Social, and Governance), the social good delivered by robust healthcare systems are at the core of healthy populations. The Covid-19 pandemic has demonstrated how vital patient access to quality and affordable healthcare is for patients all over the world. Climate change and ESG. Drug pricing and gouging.

Pharma Companies 130

Pharma Companies Clinical Trials Clinical Trials Drugs 130

Pharmaceutical Technology

JUNE 5, 2023

Pralsetinib is under clinical development by F. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases.

In-Vitro 100

In-Vitro Drugs Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

According to Globaldata, it is involved in 10 clinical trials, of which 4 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Retatrutide’s valuation in its risk-adjusted NPV model (rNPV). The drug candidate is administered through subcutaneous route.

Sales 113

Sales Production Clinical Trials Clinical Trials 113

Pharmaceutical Technology

MARCH 31, 2023

This also demonstrates our confidence in the investment climate in Kenya and the importance of utilising mRNA technology to build resilience in healthcare security in Africa.” Recently, Moderna entered into a strategic collaboration with Generation Bio for non-viral genetic medicines development.

Manufacturing 264

Manufacturing Gene Therapy Gene Genetics 264

Pharmaceutical Technology

MAY 16, 2023

UniQure is selling a part of its royalty rights to the haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million dollars. HealthCare Royalty is a royalty acquisition company. HealthCare Royalty is a royalty acquisition company.

Gene Therapy 130

Gene Therapy Gene Sales Development 130

Pharmaceutical Technology

JANUARY 2, 2023

BI-1361849 is under clinical development by Boehringer Ingelheim International and currently in the Phase II in clinical pathway. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BI-1361849 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Drugs 100

Drugs Production Manufacturing Development 100

Pharmaceutical Technology

APRIL 13, 2023

Following the increased use of telemedicine during the Covid-19 pandemic, the potential of digital technologies in communication, data collection, and analysis has become increasingly realised by patients, healthcare systems, and clinical trial sponsors.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Dermatology 130

Pharmaceutical Technology

JULY 25, 2022

The COVID-19 pandemic triggered significant changes to the way healthcare operates. According to Tom Lenaerts, Head of Global Process Engineering at Datwyler, this transformation will reshape the entire healthcare ecosystem. Datwyler also plans to develop an ‘app store’ where it can deploy standardized applications to each machine.

Engineer 286

Engineer Packaging Packaging Production 286

Pharmaceutical Technology

APRIL 19, 2023

While Bayer’s commitment to women’s health has resulted in limited success and has fallen short of investor expectations, the pharmaceutical giant is still committed to pursuing some of its clinical-stage products, including elinzanetant and its two Phase I assets targeting endometriosis, BAY2328065 and BAY2395840, says GlobalData.

Gene Therapy 130

Gene Therapy Hormones Production Sales 130

Pharmaceutical Technology

NOVEMBER 25, 2022

The global pharmaceutical industry experienced a 30% rise in new job postings related to cybersecurity in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to a 30% increase in the previous quarter and a 70% increase versus Q3 2021.

Nurses 100

Nurses Development 100

Pharmaceutical Technology

NOVEMBER 25, 2022

The global pharmaceutical industry experienced a 7% drop in new job postings related to artificial intelligence in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to a 7% increase in the previous quarter and a 63% increase versus Q3 2021.

Scientist 100

Scientist Development 100

Pharmaceutical Technology

MAY 31, 2023

More than half (54%) of the surveyed healthcare industry professionals indicated that their sentiment towards Brexit had become more negative. A Brexit survey conducted previously by GlobalData in 2021 found that the majority (60%) of the respondents had a more neutral sentiment towards Brexit at that point.

Life Science 55

Life Science Manufacturing Regulation Medicine 55

Pharmaceutical Technology

MAY 8, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. Probiotical is a manufacturer of probiotics and synbiotics products.

Production 246

Production Research Containment Branding 246

Pharmaceutical Technology

OCTOBER 26, 2022

On October 6, in a GlobalData webinar, experts tried to answer the question ‘ Is Pharma at an ESG turning point?’ , revealing a multitude of diverse strategies for pharmaceutical companies to remain conscious of their global impacts. GlobalData is the parent company of Pharmaceutical Technology. Health disparities today.

Clinical Trials 162

Clinical Trials Clinical Trials Trials Life Science 162

XTalks

APRIL 19, 2024

CINA-iPE was developed to help detect incidental pulmonary embolism during routine CT scans of other parts of the body. Both tools represent Avicenna.AI’s focus on developing tools that integrate AI within the radiology workflow, improving the speed and accuracy of medical diagnostics. percent and 24.2 percent and 24.2

Marketing 52

Marketing Radiology Development Manufacturing 52

Pharmaceutical Technology

JULY 7, 2022

There is a lot of excitement that we could be at the start of a new era for the biopharmaceutical industry, with the hope of delivering revolutionary healthcare for previously unaddressed diseases finally becoming a reality. A new frontier in cancer research. Securing the supply chain. The industry is moving at an unprecedented speed.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Pharmaceutical Technology

MAY 18, 2023

Forbion European Acquisition has entered a definitive business combination agreement with biotechnology company enGene to create a combined biotechnology company to develop next-generation non-viral, locally administered gene therapies. The proposed transaction will conclude in the second half of 2023.

Gene Therapy 130

Gene Therapy Gene In-Vivo Life Science 130

Pharmaceutical Technology

DECEMBER 15, 2022

Since HFC replacement therapy is the mainstay of treatment for CFD, increased development of more innovative fibrinogen-based therapies will benefit both the CFD population and patients experiencing AFD. HFC products must be administered intravenously in a healthcare setting and carry risks of thrombosis.

Marketing 130

Marketing Production Genotype Development 130

Pharmaceutical Technology

OCTOBER 12, 2022

2) Software and Web Developers, Programmers, and Testers claimed a 25% share, a decrease of 8.7% The top five companies, in terms of number of jobs as tracked by GlobalData, have accounted for a combined average growth of 200% share in the overall IT recruitment activity of the UK’s pharma industry during September 2022 over August 2022.

Pharma Companies 130

Pharma Companies Development 130

Pharmaceutical Technology

FEBRUARY 18, 2023

According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Gevokizumab’s valuation in its risk-adjusted NPV model (rNPV). It is a new molecular entity (NME).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

Pharmaceutical Technology

AUGUST 12, 2022

The aim of the programme is to expedite the development, assessment and review of medical devices in order to provide timely access to patients and healthcare providers. According to GlobalData’s Epidemiology & Market Size database, around 1.2 million people in the UK and 2.7

Clinical Trials 354

Clinical Trials Clinical Trials Marketing Development 354

Pharmaceutical Technology

MAY 8, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Antibody 147

Antibody Vaccination Vaccine Dermatology 147

Pharmaceutical Technology

DECEMBER 5, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has also since granted the Great Britain marketing authorisation of Lupkynis to treat adults with active LN. Notably, Lupkynis is the first oral therapy approved by the US Food and Drug Administration (FDA) and EC for the treatment of active LN.

FDA Approval 147

FDA Approval Compliance Trials Marketing 147

Pharmaceutical Technology

APRIL 13, 2023

ICER uses quality-adjusted life year (QALY), a cost effectiveness metric to measure the value of a healthcare intervention. million to achieve $150,000 per QALY gained from a healthcare system perspective. Since the price of the therapies is unknown, the institute used a placeholder cost of $2 million.

Gene Therapy 147

Gene Therapy Gene FDA Approval Licensing 147

Pharmaceutical Technology

NOVEMBER 24, 2022

Gaming and social media companies are at the vanguard of metaverse development, but enterprises will lead the charge in the next three years. This shift will be driven by the future of work and digital transformation initiatives ongoing across sectors ranging from retail to healthcare and financial services. Metaverse hype.

Branding 130

Branding Development Marketing Regulation 130